This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: running a specific preclinical model for your gene therapy in combination with tofacin to optimize the product? So the question was whether we're doing preclinical studies. So there are a couple of SOD1 transgenic mouse models, G93A, G37R, et cetera. We could add, do the combination study in vivo But I'm not certain that that would be necessary before we did the study in patients. I think that we have a very good blood-based biomarker that we can use to monitor patients in terms of the amount of injury to motor neurons. And some of these animal models, they're not very predictive of what happens in the clinic, so I worry about relying too much on these animal models. Got it. Thank you.
spk00: Thank you. Again, if you would like to ask a question, please press star 1-1 on your telephone. The next question is coming from Jack Allen of Baird. Your line is open.
spk04: Great. Thank you so much for taking the follow-up. I just wanted to reach out and see if you have any comments around the ability of knocking down primates. I know I'm
spk03: Earlier this year, there was a ban of importation of these critical research assets, and I wanted to gauge your, I guess, awareness of this and any comments you have as it relates to your preclinical programs that you have ongoing.
spk01: Hi, Jack. Todd. So, that's a great question. I think the entire field is watching very carefully. We certainly are watching the non-human primate availability quite closely. To date, we have not been adversely affected by non-human primate availability. We set up agreements with multiple vendors to make sure we have options in case an issue should arise. And all I can say is that we're doing our best to mitigate any risk and watching very closely.
spk03: Great. Thank you so much.
spk00: Thank you. This concludes today's Q&A session. There are no more questions. questions in the queue, I would like to turn the call back over to Dr. Al Sanrock for closing remarks.
spk02: Thank you everyone for joining us today and for the great questions. Feel free to follow up with us directly if you have any further questions. Thanks again.
spk00: Thank you everyone for joining today's conference call. This concludes today's event. You may all disconnect and everyone have a great rest of your day.
Disclaimer